Loading
companiesCompany
Sun Pharmaceutical Industries
India's largest drug company, which owns the branded cancer drugs Odomzo and Yonsa in the US and bought the PD-L1 antibody maker Checkpoint Therapeutics in 2025.
Also called: DUSA Pharmaceuticals, Inc.DUSA Pharmaceuticals
Overview
Sun Pharma was founded in 1983 by Dilip Shanghvi and is the fourth-largest specialty generics company in the world, with revenue of about 52,600 crore rupees in 2025. Its oncology strategy mixes generics (it was among the first US generic launchers of imatinib in 2016) with branded specialty products: it acquired Odomzo (sonidegib, for basal cell carcinoma) from Novartis in 2016, won FDA approval of Yonsa (a fine-particle abiraterone acetate) on 23 May 2018, and in 2025 acquired Checkpoint Therapeutics for about 355 million dollars, gaining the anti-PD-L1 antibody cosibelimab (Unloxcyt, FDA-approved for cutaneous squamous cell carcinoma in December 2024). In India it sells a broad oncology generics range.
Headquarters
Mumbai, IN
Scorecard
All companies#35of 1244 companies, score 85
- approved products +30
- targets +8
- modalities +6
- regions +7
- 24-month regulatory events +4
- registry trials +30
5 approved, 0 in phase 3, 0 earlier, 4 targets, 908 registry studies. Formula on the scorecards page.
Type
Large pharma · SUNPHARMA.NS
Stage
Public
Website
Founded
1983
ApprovedSmall-molecule smoothened inhibitor
Sonidegib · Odomzo
Sonidegib (Odomzo) is the second hedgehog inhibitor for locally advanced basal cell carcinoma, similar in effect and side effects to vismodegib.
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis.
ApprovedAnti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)
Cosibelimab · Unloxcyt
Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice.
ApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)
Imatinib · Gleevec
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
ApprovedTopical porphyrin precursor for photodynamic therapy
Aminolevulinic acid (topical, for photodynamic therapy) · Levulan Kerastick / Ameluz
Aminolevulinic acid is painted on sun-damaged skin and then activated with a lamp, destroying actinic keratoses before they can become skin cancer; in Europe the gel is also approved for superficial basal cell carcinoma.
Similar pages
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Abiraterone acetate, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
- CompanyCipla
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- IdeaPublicly funded dose-reduction trials of expensive approved drugs
Shares Imatinib, Prices and value, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Imatinib, Prices and value.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Imatinib, Prices and value.
- Key paperBOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- CompanyNatco Pharma
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Imatinib, Prices and value, Small-molecule kinase inhibitors.
fronts
technologies
targets
drugs
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
ApprovedTopical porphyrin precursor for photodynamic therapy
Aminolevulinic acid (topical, for photodynamic therapy) · Levulan Kerastick / Ameluz
ApprovedAnti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)
Cosibelimab · Unloxcyt
ApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)
Imatinib · Gleevec
ApprovedSmall-molecule smoothened inhibitor
Sonidegib · Odomzo